Cytek Biosciences (CTKB) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CTKB Stock Alerts $6.18 -0.12 (-1.90%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 6:44 PM | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Call TranscriptMay 13 at 9:23 AM | marketbeat.comPiper Sandler Cuts Cytek Biosciences (NASDAQ:CTKB) Price Target to $8.50Piper Sandler decreased their price target on shares of Cytek Biosciences from $10.00 to $8.50 and set an "overweight" rating on the stock in a report on Monday.May 10 at 5:30 PM | finance.yahoo.comCytek Biosciences Inc (CTKB) Q1 2024 Earnings: Revenue Surges, Yet Net Loss PersistsMay 9, 2024 | markets.businessinsider.comCytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue EstimatesMay 9, 2024 | finanznachrichten.deCytek Biosciences, Inc.: Cytek Biosciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comCytek Biosciences Inc (CTKB) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | investorplace.comCTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comCytek Biosciences Reports First Quarter 2024 Financial ResultsMay 1, 2024 | marketbeat.comCytek Biosciences (CTKB) to Release Quarterly Earnings on WednesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591278)April 30, 2024 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should KnowApril 30, 2024 | globenewswire.comCytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and EuropeApril 29, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading 6.6% Higher Cytek Biosciences (NASDAQ:CTKB) Trading Up 6.6%April 29, 2024 | globenewswire.comCytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024April 27, 2024 | marketbeat.comNew York State Common Retirement Fund Grows Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)New York State Common Retirement Fund raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,947,986 shares ofApril 24, 2024 | insidertrades.comMing Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) StockApril 23, 2024 | marketbeat.comInsider Selling: Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells 20,000 Shares of StockCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the stock in a transaction on Friday, April 19th. The stock was sold at an average price of $5.87, for a total value of $117,400.00. Following the sale, the chief technology officer now directly owns 5,988,502 shares in the company, valued at $35,152,506.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link.April 14, 2024 | marketbeat.comShort Interest in Cytek Biosciences, Inc. (NASDAQ:CTKB) Increases By 16.9%Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 9,950,000 shares, a growth of 16.9% from the March 15th total of 8,510,000 shares. Approximately 8.4% of the company's shares are short sold. Based on an average daily trading volume, of 723,300 shares, the short-interest ratio is presently 13.8 days.April 13, 2024 | insidertrades.comMing Yan Sells 1,900 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) StockApril 11, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells $13,300.00 in StockCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 1,900 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $7.00, for a total transaction of $13,300.00. Following the completion of the sale, the chief technology officer now owns 6,008,502 shares of the company's stock, valued at approximately $42,059,514. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.April 8, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. increased its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,079,421 shares of the company's stock aApril 4, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading 5% Higher Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%April 2, 2024 | marketbeat.comShort Interest in Cytek Biosciences, Inc. (NASDAQ:CTKB) Rises By 9.2%Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 8,510,000 shares, an increase of 9.2% from the February 29th total of 7,790,000 shares. Currently, 7.1% of the company's shares are short sold. Based on an average trading volume of 731,300 shares, the days-to-cover ratio is currently 11.6 days.March 27, 2024 | investorplace.comCTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023March 26, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Price Down 3.3%Cytek Biosciences (NASDAQ:CTKB) Shares Down 3.3%March 21, 2024 | markets.businessinsider.comOptimistic Outlook: Cytek Biosciences Poised for Growth with New CFO AppointmentMarch 20, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Down 4.8% After Insider SellingCytek Biosciences (NASDAQ:CTKB) Shares Down 4.8% Following Insider SellingMarch 20, 2024 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc's (CTKB) Chief Technology Officer Ming Yan Sells 40,000 SharesMarch 20, 2024 | insidertrades.comCytek Biosciences, Inc. (NASDAQ:CTKB) CTO Ming Yan Sells 20,000 SharesMarch 19, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells $135,400.00 in StockCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $6.77, for a total value of $135,400.00. Following the completion of the transaction, the chief technology officer now directly owns 6,030,402 shares in the company, valued at $40,825,821.54. The sale was disclosed in a filing with the SEC, which is available through this link.March 19, 2024 | markets.businessinsider.comCytek Biosciences Names William McCombe To Succeed Patrik Jeanmonod As CFO; Reaffirms 2024 OutlookMarch 19, 2024 | globenewswire.comCytek® Biosciences Names William McCombe Chief Financial OfficerMarch 15, 2024 | finance.yahoo.comCTKB Mar 2024 5.000 putMarch 7, 2024 | globenewswire.comCytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis SolutionsMarch 7, 2024 | finanznachrichten.deCytek Biosciences, Inc.: Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 OutlookMarch 6, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)March 6, 2024 | marketbeat.comRA Capital Management L.P. Reduces Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)RA Capital Management L.P. decreased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 44.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,809,404 shares of the company's stock afteMarch 6, 2024 | marketbeat.comPiper Sandler Cuts Cytek Biosciences (NASDAQ:CTKB) Price Target to $10.00Piper Sandler lowered their price objective on shares of Cytek Biosciences from $11.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday.March 3, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Up Following Analyst UpgradeCytek Biosciences (NASDAQ:CTKB) Shares Gap Up on Analyst UpgradeMarch 2, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Takes $1.26 Million Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)Connor Clark & Lunn Investment Management Ltd. bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 228,395 shares of the company's stock, valued at appMarch 1, 2024 | seekingalpha.comCytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | investing.comCytek Biosciences earnings matched, revenue topped estimatesMarch 1, 2024 | finance.yahoo.comCytek Biosciences Reports Full Year 2023 EarningsMarch 1, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Up After Analyst UpgradeCytek Biosciences (NASDAQ:CTKB) Shares Gap Up After Analyst UpgradeMarch 1, 2024 | finance.yahoo.comCytek Biosciences Inc (CTKB) Reports Robust Revenue Growth and Positive Net Income in Q4 2023February 29, 2024 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | globenewswire.comCytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 OutlookFebruary 13, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $8.64Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $8.64February 13, 2024 | finance.yahoo.comAfter losing 27% in the past year, Cytek Biosciences, Inc. (NASDAQ:CTKB) institutional owners must be relieved by the recent gainFebruary 9, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Stake Boosted by Principal Financial Group Inc.Principal Financial Group Inc. raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 17.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 558,546 shares of the company's stock after purchFebruary 7, 2024 | marketbeat.comNew York State Common Retirement Fund Has $12.96 Million Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)New York State Common Retirement Fund lifted its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 42.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,348,015 shares of the company's sto Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. Get the name and ticker symbol for free - just click here. CTKB Media Mentions By Week CTKB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼-0.040.58▲Average Medical News Sentiment CTKB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼112▲CTKB Articles Average Week Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Standard BioTools News Quanterix News EyePoint Pharmaceuticals News Valneva News Pacific Biosciences of California News Allogene Therapeutics News Prothena News Nautilus Biotechnology News Myriad Genetics News Olink Holding AB (publ) News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithMillionaire investor and Republican donor makes surprising election predictionInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe Crypto 9-5 Escape PlanCrypto 101 MediaUrgent Nvidia WarningAltimetryCharles Payne Demystifies OptionsUnstoppable ProsperityThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
